Yamamoto K - Search Results

1

Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions.

Nakayama Y, Ino A, Yamamoto K, Takara K. Nakayama Y, et al. Among authors: yamamoto k. Biomed Rep. 2024 Oct 4;21(6):184. doi: 10.3892/br.2024.1872. eCollection 2024 Dec. Biomed Rep. 2024. PMID: 39420918 Free PMC article.

2

Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells.

Takara K, Matsubara M, Yamamoto K, Minegaki T, Takegami S, Takahashi M, Yokoyama T, Okumura K. Takara K, et al. Among authors: yamamoto k. Mol Med Rep. 2012 Mar;5(3):603-9. doi: 10.3892/mmr.2011.734. Epub 2011 Dec 22. Mol Med Rep. 2012. PMID: 22200670

3

Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.

Mizumoto A, Yamamoto K, Nakayama Y, Takara K, Nakagawa T, Hirano T, Hirai M. Mizumoto A, et al. Among authors: yamamoto k. J Pharmacol Exp Ther. 2015 Nov;355(2):152-8. doi: 10.1124/jpet.115.226639. Epub 2015 Aug 25. J Pharmacol Exp Ther. 2015. PMID: 26306766

4

Induction of Cross-resistance to ABCB1 Substrates in Venetoclax-resistant Human Leukemia HL60 Cells.

Nakayama Y, Takara K, Minegaki T, Yamamoto K, Omura T, Yano I. Nakayama Y, et al. Among authors: yamamoto k. Anticancer Res. 2021 Sep;41(9):4239-4248. doi: 10.21873/anticanres.15228. Epub 2021 Sep 1. Anticancer Res. 2021. PMID: 34475043

5

Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.

Nakayama Y, Enomoto D, Yamamoto K, Takara K. Nakayama Y, et al. Among authors: yamamoto k. Anticancer Res. 2023 Oct;43(10):4349-4357. doi: 10.21873/anticanres.16630. Anticancer Res. 2023. PMID: 37772579

6

Down-regulation of ABCB1 in Everolimus-resistant Renal Cell Carcinoma Cells.

Nakayama Y, Ino A, Yamamoto K, Takara K. Nakayama Y, et al. Among authors: yamamoto k. Anticancer Res. 2024 Jul;44(7):2871-2876. doi: 10.21873/anticanres.17099. Anticancer Res. 2024. PMID: 38925842

7

Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells.

Takara K, Hayashi R, Kokufu M, Yamamoto K, Kitada N, Ohnishi N, Yokoyama T. Takara K, et al. Among authors: yamamoto k. Drug Chem Toxicol. 2009;32(4):332-7. doi: 10.1080/01480540903130658. Drug Chem Toxicol. 2009. PMID: 19793025

8

Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.

Takara K, Fujita M, Minegaki T, Yamamoto K, Takahashi M, Yokoyama T, Okumura K. Takara K, et al. Among authors: yamamoto k. Eur J Pharm Sci. 2012 Feb 14;45(3):272-81. doi: 10.1016/j.ejps.2011.11.023. Epub 2011 Dec 3. Eur J Pharm Sci. 2012. PMID: 22155546

9

Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.

Takara K, Yamamoto K, Matsubara M, Minegaki T, Takahashi M, Yokoyama T, Okumura K. Takara K, et al. Among authors: yamamoto k. PLoS One. 2012;7(2):e30697. doi: 10.1371/journal.pone.0030697. Epub 2012 Feb 15. PLoS One. 2012. PMID: 22355323 Free PMC article.

10

Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.

Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, Yokoyama T. Takara K, et al. Among authors: yamamoto k. Cancer Lett. 2009 Jun 8;278(1):88-96. doi: 10.1016/j.canlet.2008.12.033. Epub 2009 Feb 6. Cancer Lett. 2009. PMID: 19201079

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,664 results

Search Page

Filters